Sofiva Genomics Co., Ltd. AI Stock Analysis
Sofiva Genomics Co., Ltd. (6615) AI Stock Analysis
Sofiva Genomics Co., Ltd.
(TPEx:6615)
Sofiva Genomics scores below average, driven mainly by deteriorating financial performance: revenue has declined to NT$386 million with margin compression and a swing to a net loss, while cash generation has thinned to NT$15 million of operating cash flow. The standout positive is a fortress balance sheet — nearly debt-free with equity funding ~87% of assets — which buys management time for a turnaround, but capital is currently earning negative returns. Technicals reinforce caution, with the price below all key moving averages and a negative MACD. Valuation adds further pressure, as a 49.7x P/E is difficult to justify against falling revenue, and the 0.91% dividend yield offers limited compensation. A re-rating would require revenue stabilization and a realignment of the operating cost base.
Sofiva Genomics Co., Ltd. (6615) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 692.07M
- Dividend Yield
- 0.93%
- Average Volume (3M)
- 12.08K
- Price to Earnings (P/E)
- 48.5
- Beta (1Y)
- 0.19
- Revenue Growth
- -6.67%
- EPS Growth
- ―
- Country
- TW
- Employees
- 15
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Diagnostics & Research
Sofiva Genomics Co., Ltd. Business Overview & Revenue Model
Company Description
Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan, offers a comprehensive range of genetic testing services to both domestic and international clients. The company's diverse diagnostic solutions are designed to support expecta...
Sofiva Genomics Co., Ltd. Financial Statement Overview
Summary
A mixed but overall weak profile. Earnings are the main drag (score 28): revenue has fallen to NT$386 million, down roughly 15% year-over-year and declining in most of the past five years, gross margin has compressed from ~35% to ~26%, and the company swung to a NT$9 million net loss with EBITDA collapsing to NT$8 million. Cash flow is modest but positive (score 45) — NT$15 million operating cash flow and NT$7 million free cash flow — though both are well below 2021 levels and capex absorbs about half of operating cash. The balance sheet is the clear offset (score 76): debt of just NT$36 million against NT$628 million of equity (debt-to-equity ~0.06) funds ~87% of assets, providing substantial staying power, albeit with returns on equity now slightly negative at -1.5%.
Income Statement
28NegativeBalance Sheet
76PositiveCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 379.21M | 385.71M | 453.31M | 466.80M | 495.77M | 508.42M |
| Gross Profit | 100.71M | 99.13M | 135.66M | 129.91M | 148.99M | 176.81M |
| EBITDA | 52.80M | 7.87M | 66.34M | 27.86M | 46.58M | 77.19M |
| Net Income | 14.73M | -9.36M | 18.43M | 11.53M | 42.78M | 56.98M |
Balance Sheet | ||||||
| Total Assets | 735.62M | 724.35M | 768.08M | 767.14M | 807.56M | 822.30M |
| Cash, Cash Equivalents and Short-Term Investments | 131.52M | 124.71M | 146.18M | 140.03M | 170.96M | 245.19M |
| Total Debt | 38.30M | 35.53M | 53.38M | 63.59M | 74.67M | 90.14M |
| Total Liabilities | 87.74M | 95.91M | 123.68M | 148.77M | 180.24M | 197.86M |
| Stockholders Equity | 648.13M | 628.13M | 644.04M | 618.14M | 626.92M | 624.23M |
Cash Flow | ||||||
| Free Cash Flow | 27.40M | 7.20M | 10.57M | -859.00K | -18.56M | 67.42M |
| Operating Cash Flow | 30.38M | 15.36M | 34.69M | 23.70M | 17.14M | 80.07M |
| Investing Cash Flow | -2.79M | -14.44M | -10.66M | -9.99M | -53.48M | -10.03M |
| Financing Cash Flow | -10.79M | -22.28M | -8.57M | -36.67M | -58.65M | -44.19M |
Sofiva Genomics Co., Ltd. Peers Comparison
Overall Rating
- TW:661546Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6615 | 46Neutral | TWD 696.39M | 48.48 | ― | 0.93% | -6.67% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6615 | Sofiva Genomics Co., Ltd. | 32.25 | 2.05 | 6.79% | |
| TW:4117 | General Biologicals Corp. | 7.80 | -4.65 | -37.35% | |
| TW:4732 | Naturewise Biotech & Medicals Corporation | 14.90 | -5.60 | -27.32% | |
| TW:6493 | TTBIO CORP. | 29.05 | -0.50 | -1.69% | |
| TW:6572 | PlexBio Co., Ltd. | 5.96 | -3.04 | -33.78% | |
| TW:6939 | TFBS Bioscience, Inc. | 19.40 | -4.35 | -18.32% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026